2PARK H, PARK C, KIM Y, et al. Efficacy and safety of dipep- tidyl peptidase-4 inhibitors in type 2 diabetes : meta-analysis [ J ]. Ann Pharmacother, 2012, 46 ( 11 ) : 1453 - 1469. 被引量：1
3AHRIN B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes[ J]. Expert Opin Emerg Drugs, 2008, 13 (4) :593 -607. 被引量：1
4KARAGIANNIS T, PASCHOS P, PALETAS K, et al. Dipepti- dyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis[ J]. BMJ, 2012, 344: e1369. 被引量：1
5MOHAN V, YANG W, SON HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in Chi- na, India, and Korea[J]. Diabetes Res Clin Pract, 2009, 83 (1):106-116. 被引量：1
6Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus[J]. Acta Diabetol, 2003, 40(Suppl 2): $358-$361. 被引量：1
7National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta: Centers for Disease Control and Prevention, 2008 (http://www. cdc. gov/diabetes/pubs/pdf/ndfs_2007, pdf). 被引量：1
8Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Food and Drug Administration, December 2008 (www. fda. gov/downloads/ Drugs/Guidance Compliance Regulatory Information/ Guidances/ ucm071627, pdf). 被引量：1
9Jose T, lnzucchi SE. Cardiovascular effects of the DPP-4 inhibitors[J]. Diab Vasc Dis Res, 2012, 9: 109-116. 被引量：1
10Mannucci E, Dicembrini I. Incretin-based therapies and cardiovascular risk[J]. Curr Med Res Opin, 2012, 28(5): 715-721. 被引量：1
